Related Experiment Video
Updated: Jun 3, 2026

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
Published on: June 6, 2025
Crisis of confidence: antidepressant risk versus benefit
Andrew A Nierenberg1, Andrew C Leon, Lawrence H Price
1Department of Psychiatry, Harvard Medical School and Massachusetts General Hospital, Boston, USA.
Abstract:
Andrew A. Nierenberg, MD, assembled a group of experts to discuss recent research and lay media reports about the safety and efficacy of antidepressants for treating mild-to-moderate depression, including recent controversy surrounding antidepressant-related suicidality. The panel agreed that the data regarding the efficacy of antidepressants are complex, making it easy to misinterpret meta-analysis results. Additionally, the issue of suicidality is quite complicated, but the risk is not great enough to abandon the use of antidepressants, although patients should be monitored carefully. The panel discussed that patients who have mild or moderate depression may benefit from receiving evidence-based psychotherapy first, instead of antidepressants. The panel stressed that additional research and novel treatments are needed to improve outcomes for patients with depression. However, measurement-based pharmacotherapy is an effective tool for helping many patients with depression achieve remission and recovery. Clear communication with the public, the media, and nonpsychiatric clinicians about the safety and efficacy of antidepressants will encourage those who need treatment to seek it.
Insights
Antidepressant efficacy data is complex, but risks do not outweigh benefits for depression. Careful monitoring and clear communication are crucial for effective treatment and patient recovery.
Area of Science:
- Psychiatry
- Clinical Psychology
Background:
- Experts convened to review antidepressant safety and efficacy for mild-to-moderate depression.
- Recent media reports and research on antidepressant-related suicidality were discussed.
Discussion:
- Antidepressant efficacy data is complex and prone to misinterpretation, especially meta-analyses.
- Suicidality risk with antidepressants is a concern but not a reason to discontinue treatment with careful patient monitoring.
- Evidence-based psychotherapy may be a beneficial first-line treatment for mild-to-moderate depression.
Key Insights:
- Measurement-based pharmacotherapy is effective for depression remission and recovery.
- Clear communication regarding antidepressant safety and efficacy is vital for encouraging treatment seeking.
Outlook:
- Further research and novel treatments are necessary to enhance depression treatment outcomes.
- Improved public, media, and clinician understanding of antidepressants can facilitate necessary care.
Related Concept Videos
Antidepressant Drugs: Overview
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Antidepressant Drugs: MAOIs and Other Agents
Benefits of Self-Esteem
Depression: Overview
Drug Therapy
Antianxiety Medications